Stay updated with breaking news from Five Prime. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer - read this article along with other careers information, tips and advice on BioSpace
A physician and professor at the University of Chicago entered a plea of not guilty Tuesday to charges that he traded on inside information from Five Prime Therapeutics Inc. ahead of the publication of positive results of a drug trial for its leading cancer drug bemarituzumab.
Dr Daniel Catenacci, the lead investigator in a clinical trial for the drug bemarituzumab, has been charged with violating the antifraud provisions of the federal securities laws.
A physician and professor at the University of Chicago has been accused of trading on inside information from Five Prime Therapeutics Inc. ahead of the publication of positive results of a drug trial for its leading cancer drug bemarituzumab, prosecutors said Monday.
<p><span>The Securities and Exchange Commission today announced charges against Daniel V.T. Catenacci for insider trading in the securities of biotechnology company Five Prime Therapeutics, Inc. in advance of the company’s November 10, 2020 announcement that it had achieved positive drug trial results for its flagship cancer drug Bemarituzumab.</span></p>